Company Description
Cerus Corporation operates as a biomedical products company.
The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment.
It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally.
The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996.
The company was incorporated in 1991 and is headquartered in Concord, California.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jan 30, 1997 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Vivek Jayaraman |
Contact Details
Address: 1220 Concord Avenue, Suite 600 Concord, California 94520 United States | |
| Phone | 925 288 6000 |
| Website | cerus.com |
Stock Details
| Ticker Symbol | CERS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001020214 |
| CUSIP Number | 157085101 |
| ISIN Number | US1570851014 |
| Employer ID | 68-0262011 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Vivek K. Jayaraman | Chief Executive Officer, President and Director |
| William M. Greenman | Executive Chairman of the Board |
| Kevin D. Green CPA | Vice President of Finance and Chief Financial Officer |
| Chrystal N. Jensen J.D. | Chief Legal Officer, General Counsel and Secretary |
| Dr. Richard J. Benjamin MBChB, Ph.D. | Chief Medical Officer |
| Timothy J. Lee | Head of Investor Relation |
| Lainie Corten | Vice President of Global Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2026 | 144 | Filing |
| Jul 10, 2026 | 8-K | Current Report |
| Jun 9, 2026 | 144 | Filing |
| Jun 8, 2026 | 8-K | Current Report |
| Jun 3, 2026 | 8-K | Current Report |
| May 29, 2026 | SD | Form - SD |
| May 29, 2026 | 144 | Filing |
| May 1, 2026 | 144 | Filing |
| May 1, 2026 | 144 | Filing |
| Apr 30, 2026 | 10-Q | Quarterly Report |